title: Tachyphylaxis and bevacizumab.
authors.forename: Konstantinos N
authors.initials: KN
authors.lastname: Avgikos
authors.forename: Simon E
authors.initials: SE
authors.lastname: Horgan
authors.forename: Ramesh R
authors.initials: RR
authors.lastname: Sivaraj
authors.forename: Kuang
authors.initials: K
authors.lastname: Hu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005122:Exudates and Transudates; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D012160:Retina / Q000473:pathology; D019233:Retreatment; D013618:Tachyphylaxis; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide